Takeda Pharmaceutical (NYSE:TAK) Updates FY 2025 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 3.180-3.180 for the period. The company issued revenue guidance of $29.7 billion-$29.7 billion.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Down 3.3%

Shares of NYSE TAK traded down $0.47 during midday trading on Tuesday, reaching $13.72. 1,581,176 shares of the company's stock were exchanged, compared to its average volume of 1,902,324. Takeda Pharmaceutical has a 52-week low of $12.58 and a 52-week high of $15.43. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The stock has a market capitalization of $43.66 billion, a PE ratio of 34.30, a price-to-earnings-growth ratio of 0.24 and a beta of 0.26. The business's fifty day moving average price is $14.86 and its two-hundred day moving average price is $14.00.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. The company had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. Analysts forecast that Takeda Pharmaceutical will post 1.64 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.